Instrument Inactif

Autres langues Impax Laboratories Inc Nasdaq

Actions

US45256B1017

Produits pharmaceutiques

Autres langues

30/07	Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year of 2026
30/07	Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Amneal Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Raises 2026 Guidance
30/07	(AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Revenue Range $3.10B - $3.20B, vs. FactSet Est of $3.11B
30/07	(AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Adjusted EPS Range $0.96 - $1.06, vs. FactSet Est of $0.97
30/07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q2 Revenue $796.2M, vs. FactSet Est of $768.2M
30/07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.30 per Share, vs. FactSet Est of $0.22
30/07	Amneal: Q2 Earnings Snapshot
30/07	Amneal Reports Second Quarter 2026 Financial Results
17/07	Amneal Pharmaceuticals Receives Fda Approval for Additional Strengths and Presentations of Iohexol Injection
17/07	Amneal Pharmaceuticals Wins FDA Approval for Additional Generic Iohexol Injection Products
17/07	Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026
08/07	Amneal Pharmaceuticals : and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
01/07	Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program
01/07	Adalvo and Amneal Pharmaceuticals Receive FDA Acceptance For Review Of Two ANDAs For Generic Tirzepatide Autoinjector
29/06	Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program
29/06	Lilly, Regeneron selected for US program to review new manufacturing plants faster
29/06	Zambon and Amneal Pharmaceuticals Receive Positive CHMP Opinion for Hopledo for Adults with Parkinson?S Disease and Moderate to Severe Motor Fluctuations
29/06	Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06	Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index
29/06	Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index